Literature DB >> 16685384

Relation of DNA ploidy to genetic aberrations detected by chromosomal CGH and FISH in gastric adenocarcinomas.

Tomoko Furuya1, Tetsuji Uchiyama, Atsushi Adachi, Yasuyo Chochi, Atsunori Oga, Shigeto Kawauchi, Kimio Ishiglo, Kohsuke Sasaki.   

Abstract

We analyzed DNA copy number aberrations (DCNAs) by chromosomal comparative genomic hybridization (CGH) in 93 consecutive sporadic gastric adenocarcinomas. In addition, numerical aberrations in chromosomes 7, 11, 17, and 18 were evaluated by fluorescence in situ hybridization (FISH). Gastric cancers were divided on the basis of nuclear DNA content measured by laser scanning cytometry (LSC) into two groups, 36 DNA diploid (1.0 <or= DNA index (DI) < 1.2) and 57 aneuploid (DI >or= 1.2) cancers. The most frequent gain and loss of DNA copy number were found at 8q21-23 and 19p13.3, respectively, in both diploid and aneuploid cancers. Diploid cancers were further divided on the basis of genetic aberrations into major type and subtype cancers. The diploid cancer group included nine subtype cancers that showed large numbers of DCNAs; the mean number of DCNAs detected by CGH was 26.7 per tumor. This value was much larger in these diploid subtype cancers than diploid major type cancers (mean, 5.2 per tumor, p<0.0001). These nine cancers were also characterized by large intercellular variations in chromosome copy numbers that were not detected in the 27 major diploid type cancers. The aneuploid cancer group included only three subtype tumors that showed only a small number of DCNAs (mean, 3 per tumor) and minimal intercellular variations in chromosomal copy number. These data indicate that gastric adenocarcinomas can be divided into three types; aneuploid, major diploid type and diploid subtype cancers. Large-scale studies are necessary to clarify the differences in biological characteristics and underlying genetic mechanisms between these types.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16685384     DOI: 10.3892/or.15.6.1491

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.

Authors:  Luc G T Morris; Barry S Taylor; Trever G Bivona; Yongxing Gong; Stephanie Eng; Cameron W Brennan; Andrew Kaufman; Edward R Kastenhuber; Victoria E Banuchi; Bhuvanesh Singh; Adriana Heguy; Agnes Viale; Ingo K Mellinghoff; Jason Huse; Ian Ganly; Timothy A Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

2.  Hec1/Ndc80 is overexpressed in human gastric cancer and regulates cell growth.

Authors:  Ying Qu; Jianfang Li; Qu Cai; Bingya Liu
Journal:  J Gastroenterol       Date:  2013-04-17       Impact factor: 7.527

3.  Distinctions in gastric cancer gene expression signatures derived from laser capture microdissection versus histologic macrodissection.

Authors:  Hark Kyun Kim; Joseph Kim; Susie Korolevich; Il Ju Choi; Chang Hee Kim; David J Munroe; Jeffrey E Green
Journal:  BMC Med Genomics       Date:  2011-06-02       Impact factor: 3.063

4.  Array-CGH and multipoint FISH to decode complex chromosomal rearrangements.

Authors:  Eva Darai-Ramqvist; Teresita Diaz de Ståhl; Agneta Sandlund; Kiran Mantripragada; George Klein; Jan Dumanski; Stefan Imreh; Maria Kost-Alimova
Journal:  BMC Genomics       Date:  2006-12-29       Impact factor: 3.969

5.  The development of a mini-array for estimating the disease state of gastric adenocarcinoma by array CGH.

Authors:  Tomoko Furuya; Tetsuji Uchiyama; Atsushi Adachi; Takae Okada; Motonao Nakao; Atsunori Oga; Song-Ju Yang; Shigeto Kawauchi; Kohsuke Sasaki
Journal:  BMC Cancer       Date:  2008-12-30       Impact factor: 4.430

6.  A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population.

Authors:  Soroush Nasri; Helen More; Francesco Graziano; Annamaria Ruzzo; Emily Wilson; Anita Dunbier; Cushla McKinney; Tony Merriman; Parry Guilford; Mauro Magnani; Bostjan Humar
Journal:  BMC Cancer       Date:  2008-05-15       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.